Polymerization of actin in RBL-2H3 cells can be triggered through either the IgE receptor or the adenosine receptor but different signaling pathways are used.
Crosslinking of the IgE receptor on rat basophilic leukemia (RBL) cells using the multivalent antigen DNP-BSA leads to a rapid and sustained increase in the filamentous actin content of the cells. Stimulation of RBL cells through the adenosine receptor also induces a very rapid polymerization of actin, which peaks in 45-60 s and is equivalent in magnitude to the F-actin response elicited through stimulation of the IgE receptor. However, in contrast to the IgE mediated response, which remains elevated for over 30 min, the F-actin increase induced by the adenosine analogue 5'-(N-ethylcarboxamido)-adenosine (NECA) is relatively transient and returns to baseline values within 5-10 min. While previous work has shown that the polymerization of actin in RBL cells stimulated through the IgE receptor is mediated by protein kinase C (PKC), protein kinase inhibitors have no effect on the F-actin response activated through the adenosine receptor. In contrast, pretreatment of the cells with pertussis toxin completely inhibits the F-actin response to NECA but has relatively little effect on the response induced through the IgE receptor. Stimulation of RBL cells through either receptor causes increased production of phosphatidylinositol mono-phosphate (PIP) and phosphatidylinositol bis-phosphate (PIP2), which correlates with the F-actin response. Production of PIP and PIP2 may be important downstream signals since these polyphosphoinositides are able to regulate the interaction of gelsolin and profilin with actin. Thus the polymerization of actin can be triggered through either the adenosine receptor or the IgE receptor, but different upstream signaling pathways are being used. The IgE mediated response requires the activation of PKC while stimulation through the adenosine receptor is PKC independent but involves a G protein.
Apgar
J R
JR
Scripps Research Institute, La Jolla, California 92037.
D000199:Actins / Q000378:metabolism*; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D000818:Animals; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004140:Dinitrophenols / Q000276:immunology; D004789:Enzyme Activation; D019204:GTP-Binding Proteins / Q000378:metabolism; D006241:Haptens / Q000276:immunology; D019269:Phosphatidylinositol 4,5-Diphosphate; D018129:Phosphatidylinositol Phosphates / Q000096:biosynthesis; D011108:Polymers / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D017455:Receptors, IgE / Q000378:metabolism*; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D012710:Serum Albumin, Bovine / Q000276:immunology; D015398:Signal Transduction; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
D000199:Actins; D004140:Dinitrophenols; D006241:Haptens; D019269:Phosphatidylinositol 4,5-Diphosphate; D018129:Phosphatidylinositol Phosphates; D011108:Polymers; D017455:Receptors, IgE; D018047:Receptors, Purinergic P1; C034638:dinitrophenyl-bovine serum albumin; D012710:Serum Albumin, Bovine; D019830:Adenosine-5'-(N-ethylcarboxamide); D000242:Cyclic AMP; D011493:Protein Kinase C; D019204:GTP-Binding Proteins; D000241:Adenosine; D002118:Calcium